21 – 30 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
2023) In Annals of Oncology(
- Contribution to journal › Article
- 2022
-
Mark
Mixed Phenotype/Lineage Leukemia : Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?
(
- Contribution to journal › Scientific review
-
Mark
The Urothelial Transcriptomic Response to Interferon Gamma : Implications for Bladder Cancer Prognosis and Immunotherapy
(
- Contribution to journal › Article
-
Mark
The immune cell atlas of human neuroblastoma
(
- Contribution to journal › Article
-
Mark
Landscape of surfaceome and endocytome in human glioma is divergent and depends on cellular spatial organization
2022) In Proceedings of the National Academy of Sciences of the United States of America 119(9). p.1-11(
- Contribution to journal › Article
-
Mark
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
(
- Contribution to journal › Article
- 2021
-
Mark
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
(
- Contribution to journal › Article
-
Mark
Local Destruction of Tumors and Systemic Immune Effects
(
- Contribution to journal › Scientific review
-
Mark
Immunomodulation—A Molecular Solution to Treating Patients with Severe Bladder Pain Syndrome?
(
- Contribution to journal › Article
-
Mark
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
(
- Contribution to journal › Article